Chosa Oncology Management
Management criteria checks 0/4
We currently do not have sufficient information about the CEO.
Key information
Peter Jensen
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | no data |
| CEO ownership | n/a |
| Management average tenure | no data |
| Board average tenure | 1.7yrs |
Recent management updates
Recent updates
CEO
Peter Jensen (69 yo)
no data
Tenure
Mr. Peter Buhl Jensen, Adj Professor, MD, PhD is Chief Executive Officer of RhoVac AB. He is Director at Respiratorius AB (publ). He has been Independent Chairman of the Board at Amniotics AB (publ) since...
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| COO & Board Member | 1.7yrs | no data | no data | |
| Chief Commercial Officer & Board Member | 1.7yrs | no data | no data | |
| Director | 1.7yrs | no data | no data | |
| Board Chair | 1.7yrs | no data | no data | |
| Director | less than a year | no data | no data |
1.7yrs
Average Tenure
60yo
Average Age
Experienced Board: W5L's board of directors are not considered experienced ( 1.7 years average tenure), which suggests a new board.